文献速递神经肌肉病

ChAdOx1-S/nCoV-19疫苗接种后吉兰-巴雷综合征

Guillain-Barré Syndrome following ChAdOx1-S/nCoV-19 Vaccine.
PubMed 文献 · Ann Neurol · 2021-06-22

2021年3月中旬至4月中旬4周内观察到7例首剂接种后2周内发生的吉兰-巴雷综合征(GBS),均为重型,GBS频率为该规模人群同期预期值的1.4至10倍。

要点

  • 接种ChAdOx1-S/nCoV-19疫苗后2周内可出现GBS,本组7例均为重型。
  • 本组GBS频率为同期预期值的1.4至10倍,双侧面肌无力模式提示与疫苗接种相关。
  • 7例中6例进展为无反射性四肢瘫并需机械通气支持。

核心结论

  • ChAdOx1-S/nCoV-19疫苗接种后可能发生吉兰-巴雷综合征,本组频率高于同期预期,但该结局相对罕见(5.8/百万),疫苗接种获益仍显著大于风险。

主要发现

  • 2021年3月中旬至4月中旬4周内观察到7例首剂接种后2周内发生的GBS,全部为重型。
  • 本组GBS频率为该规模人群同期预期值的1.4至10倍。
  • 7例中6例进展为无反射性四肢瘫并需要机械通气支持。
  • 双侧面肌无力频率提示与疫苗接种相关的模式,该表现通常见于不到20%的GBS病例。

关键数值与推荐

  • GBS发生频率为5.8/百万。
  • 双侧面肌无力通常发生于不到20%的GBS病例。

临床怎么用

  • 临床医生应警惕ChAdOx1-S/nCoV-19疫苗接种后2周内可能发生的GBS,尤其是重型表现。
  • 接种后出现GBS症状者应评估进展为无反射性四肢瘫及需要机械通气的风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

As of April 22, 2021, around 1.5 million individuals in three districts of Kerala, India had been vaccinated with COVID-19 vaccines. Over 80% of these individuals (1.2 million) received the ChAdOx1-S/nCoV-19 vaccine. In this population, during this period of 4 weeks (mid-March to mid-April 2021), we observed seven cases of Guillain-Barre syndrome (GBS) that occurred within 2 weeks of the first dose of vaccination. All seven patients developed severe GBS. The frequency of GBS was 1.4- to 10-fold higher than that expected in this period for a population of this magnitude. In addition, the frequency of bilateral facial weakness, which typically occurs in <20% of GBS cases, suggests a pattern associated with the vaccination. While the benefits of vaccination substantially outweigh the risk of this relatively rare outcome (5.8 per million), clinicians should be alert to this possible adverse event, as six out of seven patients progressed to areflexic quadriplegia and required mechanical ventilatory support. ANN NEUROL 2021;90:312-314.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Maramattom BV, Krishnan P, Paul R, et al. Guillain-Barré Syndrome following ChAdOx1-S/nCoV-19 Vaccine. Ann Neurol. 2021. PMID: 34114256. doi:10.1002/ana.26143

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。